Essex Bio-Technology (1061) AI Stock Analysis

• Market Cap: HK$2.57B
• Dividend Yield: 3.02%
• Average Volume (3M): 863.25K
• Price to Earnings (P/E): 8.2
• Beta (1Y): 0.56
• Revenue Growth: 7.16%
• EPS Growth: 19.19%
• Country: HK
• Employees: 1,450
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.29
• Shares Outstanding: 567,006,000
• 10 Day Avg. Volume: 975,600
• 30 Day Avg. Volume: 863,250
• PEG Ratio: 0.53
• Price to Book (P/B): 0.79
• Price to Sales (P/S): 1.00
• P/FCF Ratio: 5.15
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 64 Neutral
• Price Target: HK$5.00 ▲(16.28% Upside)

Essex Bio-Technology's strong financial performance and attractive valuation are offset by bearish technical indicators. The company's solid balance sheet and profitability are strengths, but recent revenue declines and technical weakness present risks. The stock's low P/E ratio and dividend yield provide some upside potential.

Essex Bio-Technology Business Overview & Revenue Model

Company Description

Essex Bio-Technology Limited, an investment holding company, develops, manufactures, distributes, and sells biopharmaceutical products in the People's Republic of China and internationally. The company operates through Ophthalmic Products and Surgical Products segments. It researches and develops basic fibroblast growth factor products for the treatment of cellular proliferation, differentiation, and migration. The company offers Beifushu series, such as Beifushu eye drops, Beifushu eye gel, and Beifushu unit-dose eye drops; Tobramycin eye drops, Levofloxacin eye drops, and Sodium Hyaluronate eye drops, as well as Iodized Lecithin Capsules. It also provides Beifuji sprays and lyophilized powder, and Beifuxin gels for use in burn and scald wounds, acute wounds, surgical incisions, chronic wounds, skin grafting, and other applications. In addition, it offers ophthalmic and surgical products from third parties. Further, the company offers Carisolv dental caries removal gel; and Yi Xue An Granules. It has license agreements with Mitotech S.A. and Mitotech LLC. The company was founded in 1990 and is headquartered in Zhuhai, China.

How the Company Makes Money

Essex Bio-Technology generates revenue primarily through the sale of its pharmaceutical products, which are developed to address medical needs in ophthalmology and dermatology. The company's revenue streams are largely driven by its proprietary biologics and pharmaceuticals marketed under various brand names. In addition to direct product sales, the company may also engage in strategic partnerships and collaborations with other pharmaceutical firms to expand its market reach and enhance its product offerings. These partnerships can involve co-development, co-marketing, or licensing agreements, contributing to both revenue growth and market penetration. The company invests in research and development to continually enhance its product pipeline, ensuring a steady flow of innovative treatments to maintain and grow its market share.

Essex Bio-Technology Financial Statement Overview

Summary

Essex Bio-Technology demonstrates solid profitability and a strong balance sheet, although recent revenue declines and fluctuating cash flows present challenges. The company remains financially stable with strong equity support but should focus on reversing revenue trends to enhance growth.

Income Statement

Essex Bio-Technology shows a strong gross profit margin and consistent net profit margin, reflecting solid profitability. However, recent revenue growth has been negative, indicating a potential concern for future earnings. EBIT and EBITDA margins remain stable, showcasing efficient operations.

Balance Sheet

The company maintains a healthy debt-to-equity ratio and strong return on equity, indicating effective use of equity financing and operational efficiency. The equity ratio is robust, emphasizing a strong capital structure with significant equity backing.

Cash Flow

While operating cash flow supports net income well, fluctuating free cash flow growth rates suggest volatility in capital expenditures and cash reserves. The free cash flow to net income ratio indicates effective conversion of profits into cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.73B	1.67B	1.71B	1.32B	1.64B	978.11M
Gross Profit	1.55B	1.50B	1.54B	1.19B	1.40B	793.83M
EBITDA	435.67M	400.71M	418.38M	313.54M	436.65M	279.50M
Net Income	313.18M	307.22M	275.26M	225.41M	345.97M	218.93M
Balance Sheet
Total Assets	3.23B	2.98B	2.83B	2.71B	2.86B	2.42B
Cash, Cash Equivalents and Short-Term Investments	642.92M	560.74M	515.03M	543.49M	671.35M	599.80M
Total Debt	291.25M	187.04M	294.02M	489.73M	565.19M	562.77M
Total Liabilities	959.94M	859.33M	903.78M	981.03M	1.13B	995.15M
Stockholders Equity	2.27B	2.12B	1.92B	1.73B	1.73B	1.43B
Cash Flow
Free Cash Flow	253.46M	324.07M	211.16M	99.87M	164.63M	-18.40M
Operating Cash Flow	359.29M	368.47M	339.21M	382.79M	409.16M	299.24M
Investing Cash Flow	-181.34M	-106.59M	-54.34M	-302.03M	-280.08M	-343.27M
Financing Cash Flow	-144.83M	-200.81M	-309.92M	-169.11M	-73.13M	149.49M

Essex Bio-Technology Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.30
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1061, the sentiment is Negative. The current price of 4.3 is below the 20-day moving average (MA) of 4.65, below the 50-day MA of 5.07, and above the 200-day MA of 4.27, indicating a neutral trend. The MACD of -0.22 indicates Positive momentum. The RSI at 31.89 is Neutral, neither overbought nor oversold. The STOCH value of 14.41 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1061.

Essex Bio-Technology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2877	―	HK$6.47B	7.25	10.85%	6.01%	-20.64%	-25.39%
1681	―	HK$12.45B	11.64	25.92%	4.19%	19.05%	13.68%
1061	―	HK$2.57B	8.21	14.60%	3.02%	7.16%	19.19%
0570	―	$13.04B	197.41	-1.26%	3.35%	-9.58%	-128.83%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
0460	―	$13.62B	―	-1.87%	0.74%	19.21%	-115.91%

Essex Bio-Technology Corporate Events

Essex Bio-Technology Reports Growth in Interim 2025 Financial Results

Essex Bio-Technology Limited reported its unaudited interim financial results for the first half of 2025, showing a 5.8% increase in turnover and a 3.8% rise in profit compared to the same period in 2024. Despite a slight decline in profit margins, the company experienced growth in total assets and cash reserves, indicating a stable financial position and potential for continued investment in its core biopharmaceutical operations.

The most recent analyst rating on (HK:1061) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Essex Bio-Technology stock, see the HK:1061 Stock Forecast page.

Essex Bio-Technology Declares Interim Dividend for 2025

Essex Bio-Technology Limited announced an interim dividend of HKD 0.07 per share for the six months ending June 30, 2025. This announcement reflects the company’s financial performance and commitment to returning value to shareholders, potentially enhancing its market position and investor confidence.

The most recent analyst rating on (HK:1061) stock is a Buy with a HK$6.50 price target. To see the full list of analyst forecasts on Essex Bio-Technology stock, see the HK:1061 Stock Forecast page.

Essex Bio-Technology to Review Interim Results and Dividend

Essex Bio-Technology Limited has announced that its board of directors will hold a meeting on August 26, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The board will also consider the potential declaration of an interim dividend, which could impact the company’s financial strategy and shareholder returns.

Essex Bio-Technology’s HLX04-O Application Accepted in China

Essex Bio-Technology Limited has announced that its Biologics License Application for HLX04-O, an anti-VEGF ophthalmic injection developed for the treatment of wet-AMD, has been accepted by the Centre for Drug Evaluation in China. This development is significant as there is currently no approved bevacizumab product for wet-AMD in the Chinese market, where sales for similar treatments reached approximately RMB4.9 billion in 2024. The acceptance of this application marks a critical step in the potential commercialization of HLX04-O, which could enhance Essex Bio-Technology’s market positioning and offer a new treatment option for wet-AMD patients.